Assessment of metabolic syndrome in infertile women with polycystic ovary syndrome in a rural population of South India: A crosssectional study


Background: Polycystic ovary syndrome (PCOS) is known to be associated with metabolic syndrome (MS). It is characterised by insulin resistance, hyperinsulinemia, dyslipidemia, obesity and hypertension. Data related to MS in infertile women with PCOS are limited in Indian populations.

Objective: This study aims to compare the prevalence of MS in infertile women with and without PCOS in a rural population in South India.

Materials and Methods: 130 women with PCOS and 130 women without PCOS were enrolled in this cross-sectional study. A detailed history was taken and a physical examination was done for all women. Anthropometric parameters, a glucose tolerance test, fasting glucose / insulin levels, trigylcerides, high-density lipoprotein cholesterol and blood pressure were assessed in all participants. The International Diabetes Federation criteria were applied for assessment of MS.

Results: MS was more prevalent in infertile women with PCOS (42.3%) compared to women without PCOS (19.3%). 56.9% of women with PCOS had low high-density lipoprotein cholesterol levels, 46.2% had high triglycerides, 71.5% had a high waist circumference, 31.5% had high blood pressure and 37.7% had high blood glucose levels. 26.0% of the women with PCOS had a healthy weight, and MS was seen in 6.9% of these women.

Conclusion: The prevalence of MS was higher in women with PCOS in comparison to women without PCOS. Among the women with PCOS, the prevalence of MS increased with age (> 27 yr), body mass index and waist circumference (71.5%), and even healthy women with PCOS contributed to 7% of MS. Hence it becomes necessary to screen all women with PCOS for metabolic profile risk factors at young age itself to prevent long term cardiovascular complications.

Key words: Polycystic ovary syndrome, Metabolic syndrome, Hyperandrogenism, Hormones.

[1] Ashraf Ganie M, Vasudevan V, Wani IA, Baba MS, Arif T, Rashid A. Epidemiology, pathogenesis, genetics & management of polycystic ovary syndrome in India. Indian J Med Res 2019; 150: 333–344.

[2] Nidhi R, Padmalatha V, Nagarathna R, Amritanshu R. Prevalence of polycystic ovarian syndrome in Indian adolescents. J Pediatr Adolesc Gynecol 2011; 24: 223–227.

[3] Nair MKC, Pappachan P, Balakrishnan Sh, Leena ML, George B, Russell PS. Menstrual irregularity and polycystic ovarian syndrome among adolescent girls: A two year follow-up study. Indian J Pediatr 2012; 79 (Suppl.): 69–73.

[4] Krentowska A, Lebkowska A, Jacewicz-Swięcka M, Hryniewicka J, Lesniewska M, Adamska A, et al. Metabolic syndrome and the risk of cardiovascular complications in young patients with different phenotypes of polycystic ovary syndrome. Endocrine 2021; 72: 400–410.

[5] Hillman JK, Johnson LNC, Limaye M, Feldman RA, Sammel M, Dokras A. Black women with polycystic ovary syndrome (PCOS) have increased risk for metabolic syndrome and cardiovascular disease compared with white women with PCOS. Fertil Steril 2014; 101: 530–535.

[6] Behboudi-Gandevani S, Ramezani Tehrani F, Rostami Dovom M, Farahmand M, Khomami MB, Noroozzadeh M, et al. Insulin resistance in obesity and polycystic ovary syndrome: Systematic review and meta-analysis of observational studies. Gynecol Endocrinol 2016; 32: 343– 353.

[7] Parikh RM, Mohan V. Changing definitions of metabolic syndrome. Indian J Endocrinol Metab 2012; 16: 7–12.

[8] Serbis A, Giapros V, Galli-Tsinopoulou A, Siomou E. Metabolic syndrome in children and adolescents: Is there a universally accepted definition? Does it matter? Metab Syndr Relat Disord 2020; 18: 462–470.

[9] Jamil AS, Alalaf ShK, Al-Tawil NG, Al-Shawaf T. A casecontrol observational study of insulin resistance and metabolic syndrome among the four phenotypes of polycystic ovary syndrome based on Rotterdam criteria. Reprod Health 2015; 12: 7.

[10] Shabir I, Ashraf Ganie M, Zargar MA, Bhat D, Mir MM, Jan A, et al. Prevalence of metabolic syndrome in the family members of women with polycystic ovary syndrome from North India. Indian J Endocrinol Metab 2014; 18: 364–369.

[11] Park HR, Choi Y, Lee HJ, Oh JY, Hong YS, Sung YA. The metabolic syndrome in young Korean women with polycystic ovary syndrome. Diabetes Res Clin Pract 2007; 77 (Suppl.): 243–246.

[12] Glueck ChJ, Morrison JA, Goldenberg N, Wang P. Coronary heart disease risk factors in adult premenopausal white women with polycystic ovary syndrome compared with a healthy female population. Metabolism 2009; 58: 714–721.

[13] Tavares A, Barros RCR. The prevalence of metabolic syndrome in the different phenotypes of polycystic ovarian syndrome. Rev Bras Ginecol Obstet 2019; 41: 37–43.

[14] Alberti KGMM, Zimmet P, Shaw J, IDF Epidemiology Task Force Consensus Group. The metabolic syndrome: A new worldwide definition. Lancet 2005; 366: 1059–1062.

[15] Mafaldo Soares EM, Azevedo GD, Nóbrega Gadelha RG, Moura Lemos TMA, Oliveira Maranhao TM. Prevalence of the metabolic syndrome and its components in Brazilian women with polycystic ovary syndrome. Fertil Steril 2008; 89: 649– 655.

[16] Bahadur A, Mundhra R, Kashibhatla J, Rajput R, Verma N, Kumawat M. Prevalence of metabolic syndrome among women with different PCOS phenotypes: A prospective study. Gynecol Endocrinol 2021; 37: 21–25.

[17] Cheung LP, Ma RCW, Lam PM, Lok IH, Haines CJ, So WY, et al. Cardiovascular risks and metabolic syndrome in Hong Kong Chinese women with polycystic ovary syndrome. Hum Reprod 2008; 23: 1431–1438.

[18] Hallajzadeh J, Khoramdad M, Karamzad N, Almasi-Hashiani A, Janati A, Ayubi E, et al. Metabolic syndrome and its components among women with polycystic ovary syndrome: A systematic review and meta-analysis. J Cardiovasc Thorac Res 2018; 10: 56–69.

[19] Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 2004; 81: 19–25.

[20] Mandrelle K, Kamath MS, Bondu DJ, Chandy A, Aleyamma TK, George K. Prevalence of metabolic syndrome in women with polycystic ovary syndrome attending an infertility clinic in a tertiary care hospital in south India. J Hum Reprod Sci 2012; 5: 26–31.

[21] Sawant A, Mankeshwar R, Shah S, Raghavan R, Dhongde G, Raje H, et al. Prevalence of metabolic syndrome in urban India. Cholesterol 2011; 2011: 920983.

[22] Tripathy P, Sahu A, Sahu M, Nagy A. Metabolic risk assessment of Indian women with polycystic ovarian syndrome in relation to four Rotterdam criteria based phenotypes. Eur J Obstet Gynecol Reprod Biol 2018; 224: 60–65.

[23] Kutlu O. Evaluation of quality of life of patients with hirsutism among Turkish women: A single-center cross-sectional study. J Cosmet Dermatol 2020; 19: 3053–3057.

[24] Alowfi A, Binladen S, Irqsous S, Khashoggi A, Khan MA, Calacattawi R. Metabolic syndrome: Prevalence and risk factors among adolescent female intermediate and secondary students in Saudi Arabia. Int J Environ Res Public Health 2021; 18: 2142.

[25] Bhattacharya SM. Metabolic syndrome in females with polycystic ovary syndrome and International Diabetes Federation criteria. J Obstet Gynaecol Res 2008; 34: 62– 66.

[26] Li A, Zhang L, Jiang J, Yang N, Liu Y, Cai L, et al. Follicular hyperandrogenism and insulin resistance in polycystic ovary syndrome patients with normal circulating testosterone levels. J Biomed Res 2018; 32: 208–214.

[27] Luotola K, Piltonen TT, Puurunen J, Morin-Papunen LC, Tapanainen JS. Testosterone is associated with insulin resistance index independently of adiposity in women with polycystic ovary syndrome. Gynecol Endocrinol 2018; 34: 40–44.

[28] Li X, Lin JF. [Clinical features, hormonal profile, and metabolic abnormalities of obese women with obese polycystic ovary syndrome]. Zhonghua Yi Xue Za Zhi 2005; 85: 3266–3271. (in Chinese)

[29] Thangavelu M, Godla UR, Godi S, Paul SFD, Maddaly R. A case-controlled comparative hospital-based study on the clinical, biochemical, hormonal, and gynecological parameters in polycystic ovary syndrome. Indian J Pharm Sci 2017; 79: 608–616.

[30] Hahn S, Tan S, Sack S, Kimmig R, Quadbeck B, Mann K, et al. Prevalence of the metabolic syndrome in German women with polycystic ovary syndrome. Exp Clin Endocrinol Diabetes 2007; 115: 130–135.

[31] Stone T, Stachenfeld NS. Pathophysiological effects of androgens on the female vascular system. Biol Sex Differ 2020; 11: 45.

[32] Barber TM, Franks S. Obesity and polycystic ovary syndrome. Clin Endocrinol 2021; 95: 531–541.

[33] Abdelazim IA, Elsawah WF. Metabolic syndrome among infertile women with polycystic ovary syndrome. Asian Pacific J Reprod 2015; 4: 44–48.

[34] Apridonidze T, Essah PA, Iuorno MJ, Nestler JE. Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2005; 90: 1929–1935.